Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Memphasys Ltd ( (AU:MEM) ) has shared an announcement.
Memphasys Limited, an Australian reproductive biotech company, is commercialising its patented Felix System, which selects high-quality sperm for assisted reproduction using a rapid, low-stress process that replaces conventional centrifugation. The company targets global fertility markets through a mix of direct and distributor-led sales, with an emphasis on recurring cartridge revenues and margin expansion as installed systems grow.
The company will host an investor webinar on 8 April 2026 to update shareholders on its global commercial expansion and growing recurring revenue base. Management will outline progress in the commercial rollout of the Felix System, recent regulatory approvals enabling wider market access, early revenue traction and clinic adoption, and its strategy to scale across additional jurisdictions, signalling a transition from development to broader commercial execution.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited is an Australian-based reproductive biotechnology company focused on commercialising the Felix System, a patented bioseparation technology that isolates the most viable sperm cells for human assisted reproduction. The system uses electrophoresis and size-exclusion membranes to provide a faster, gentler, and more standardised alternative to traditional centrifugation, aiming to become a new global standard in sperm preparation for assisted reproductive technology procedures.
Memphasys is pursuing a commercial strategy centred on building contracted sales through a mix of direct and distributor-led channels in multiple geographies. The company is also scaling production to improve margins and drive recurring cartridge revenues from an installed base of Felix systems in fertility clinics worldwide.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$14.24M
Find detailed analytics on MEM stock on TipRanks’ Stock Analysis page.